Table 1.
Comparison of clinical manifestations between patients with AML in low and high BDH2 expression groupsa
| Variables | Total (n = 113) | Low BDH2, expression, (n = 57) | High BDH2, expression, (n = 56) | P |
|---|---|---|---|---|
| Sexb |
113 |
57 |
56 |
0.467 |
| Male |
64 |
23 |
26 |
|
| Female |
49 |
34 |
30 |
|
| Age (years)c |
54.5 (21–86) |
48 (22–86) |
57 (21–85) |
0.193 |
| Laboratory datac |
|
|
|
|
| WBC, ìL−1 |
30,830 |
37,615 |
24,370 (600–243,290) |
0.452 |
| (300–296,300) |
(300–216,820) |
|||
| Hb, g/dL |
8.3 |
8.3 |
8.4 |
0.365 |
| (4.2–15.6) |
(4.4–14.3) |
(4.2–15.6) |
||
| Platelet, ×1,000/ìL |
42 |
44.5 |
41 |
0.582 |
| (3–369) |
(4–175) |
(3–369) |
||
| Blast, ìL−1 |
20,188.5 |
13,074.15 |
26,001 |
0.172 |
| (0–287,411) |
(126–145,572.7) |
(0–287,411) |
||
| Blast in BM, % |
74.8% (24.8%–97.4%) |
70.8% (24.8%–94.7%) |
79% (27.2%–94.4%) |
0.424 |
| CD34 (+) in BM, % |
31.1% |
29.5% |
33.25% (0%–99.5%) |
0.272 |
| (0%–99.9%) |
(0%–99.9%) |
|||
| FABb |
|
|
|
|
| M0 |
3 |
1 (1.75%) |
2 (2.44%) |
0.057 |
| M1 |
28 |
8 (13.89%) |
20 (43.90%) |
|
| M2 |
47 |
25 (47.23%) |
22 (34.15%) |
|
| M3 |
0 |
0 (0%) |
0 (0%) |
|
| M4 |
23 |
15 (23.61%) |
9 (14.63%) |
|
| M5 |
7 |
6 (9.72%) |
1 (0%) |
|
| M6 |
0 |
0 (0%) |
0 (0%) |
|
| M7 |
4 |
2 (2.78%) |
2 (4.88%) |
|
| Undetermined |
0 |
0 (0%) |
0 (0%) |
|
| Induction responsebd |
|
|
|
|
| CR |
61 (70.93%) |
37 (80.42%)f |
24 (60%)g |
0.032* |
| PR and Refractory |
|
32 |
20 |
|
| Induction death |
|
1 |
0 |
|
| Reach CR timee |
|
|
|
|
| 38 ± 38.0 | 40.5 ± 44.3 | 36 ± 29.7 | 0.526 |
aThe median value of BDH2 expression in the total population was used as the cutoff level of 9.006 to define low- and high-expression groups.
bNumber of patients (%).
cMedian (range).
dOnly the 86 patients who received conventional intensive induction chemotherapy, and then consolidation chemotherapy if CR was achieved, were included in the analyses.
ePatients received conventional intensive induction chemotherapy and achieved CR, median, days ± S.D.
fOnly 46 patients received I3A7.
gOnly 40 patients received I3A7 (Idarubicin and Ara-C).
*Statistically significant (P < 0.05).